PDZK1IP1 and pancreatic adenocarcinoma: To assess MAP17 expression in pancreatic cancer, we analyzed its expression in a TCGA cohort of pancreatic adenocarcinoma patients which included both normal and tumor samples and we found that MAP17 levels were significantly elevated in tumor samples compared to normal samples (Figure 1A).